Antigonadotropin
| Drug | Dosage | Remarks |
|---|---|---|
| Danazol | 200 mg PO 24 hourly for 12 weeks |
Adverse Reactions
|
Haemostatics
| Drug | Dosage | Remarks |
|---|---|---|
| Ethamsylate | 500 mg PO 6 hourly from start of bleeding until menstruation ceases |
Adverse Reactions
|
| Tranexamic acid | 1 g PO 6-8 hourly starting at day 1 of menses for up to 5 days |
Adverse Reactions
|
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
| Drug | Dosage | Remarks |
|---|---|---|
| Anthranilic Acid Derivative |
Adverse Reactions
|
|
| Mefenamic acid | 250-500 mg PO 8 hourly beginning with onset of menses and continuing for 5 days or until cessation of flow | |
| Propionic Acid Derivative | ||
| Naproxen | 825-1,375 mg/day PO divided 12 hourly | |
Progestogens
| Drug | Dosage | Remarks |
|---|---|---|
| Levonorgestrel | 1 IUS unit inserted into the uterine cavity within 7 days of the onset of menstruation |
Adverse Reactions
|
| Lynestrenol | 10 mg PO 24 hourly for 10 days |
Adverse Reactions
|
| Medroxyprogesterone | 2.5-10 mg PO 24 hourly for 5-10 days starting on the sixteenth day of menstrual cycle |
Adverse Reactions
|
| Nomegestrol acetate | 5 mg PO 24 hourly from sixteenth to twenty-fifth day of cycle |
Adverse Reactions
|
| Norethisterone (Norethindrone) |
10-15 mg/day PO divided 8 hourly for 10 days, in a cyclical regimen |
Adverse Reactions
|
Progestogen & Estrogen Combinations
| Drug | Dosage | Remarks |
|---|---|---|
| Dienogest/estradiol valerate |
1 tab PO 24 hourly starting on day 1 of menses for 28 days |
Adverse Reactions
|
| Levonorgestrel/ethinyl estradiol1 | 1 tab PO 24 hourly starting on day 1 of menses for 21 days | |
| 1Combination with Ferrous fumarate is available. Please see the latest MIMS for specific formulations and prescribing information. | ||
Disclaimer
All dosage recommendations are for non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
